Tag: FDA

FDA: Class I recall of Cardiosave Hybrid and Rescue IABPs

Editor's Note The Food & Drug Administration on November 2 identified the recall by Maquet Datascope Corp/Getinge Group’s Cardiosave Hybrid and Cardiosave Rescue Intra-aortic Balloon Pumps (IABPs) as Class I, the most serious. The recall was initiated because of the potential for the autofill process to malfunction or fail during…

Read More

By: Judy Mathias
November 5, 2018
Share

FDA: Class I recall of CyPass Micro-Stent Systems

Editor's Note The Food & Drug Administration (FDA) on October 24 classified Alcon Research’s recall of its CyPass Micro-Stent Systems as Class I, the most serious. The recall was initiated because of the risk of corneal endothelial cell loss with the system, which is used in conjunction with cataract surgery…

Read More

By: Judy Mathias
October 30, 2018
Share

FDA: Safety Communication on Raindrop Near Vision Inlay

Editor's Note The Food & Drug Administration (FDA) on October 23 issued a Safety Communication on the increased risk of corneal haze associated with the Raindrop Near Vision Inlay, which is surgically implanted in the cornea of one eye to improve near vision. The notice is to alert eye care…

Read More

By: Judy Mathias
October 25, 2018
Share

FDA: Promise Pharmacy recalls one lot of Prednisolone, Gatifloxacin Ophthalmic Solution

Editor's Note The Food & Drug Administration (FDA) on October 22 announced the recall by Promise Pharmacy (Palm Harbor, Florida) of one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3 mL vials (Lot Number 09042018@2, Exp 12/03/2018). The recall was issued because the product was found to have…

Read More

By: Judy Mathias
October 24, 2018
Share

FDA: Class I recall of Endologix AFX Endovascular AAA System

Editor's Note The Food & Drug Administration on October 15 classified the recall by Endologix, Inc, of its AFX Endovascular AAA System as Class I, the most serious. The recall was initiated because of the risk of Type III endoleaks. When a Type III endoleak occurs, blood continues to flow…

Read More

By: Judy Mathias
October 23, 2018
Share

FDA announces public workshop on management of cybersecurity in medical devices

Editor's Note The Food & Drug Administration (FDA) on October 17 announced a public workshop to discuss the newly released draft guidance: Content of Premarket Submissions for Management of Cybersecurity in Medical Devices. The need for effective cybersecurity to ensure medical device function and safety has become more important with…

Read More

By: Judy Mathias
October 18, 2018
Share

FDA, DHS increase coordination for medical device cybersecurity

Editor's Note The Food and Drug Administration (FDA) on October 16 announced that as part of the Administration’s efforts to strengthen cybersecurity in healthcare, the FDA and Department of Homeland Security (DHS) have agreed to greater coordination and cooperation for addressing cybersecurity in medical devices. Under the agreement, DHS will…

Read More

By: Judy Mathias
October 17, 2018
Share

FDA: Endo Pharmaceuticals recalls two lots of Robaxin

Editor's Note The Food & Drug Administration on September 28 announced the recall by Endo Pharmaceuticals Inc of two lots of Robaxin 750 mg tablets because of incorrect dosing information on the label. Robaxin contains methocarbamol, which is used as a muscle relaxant. Patients who follow the incorrect dosing information…

Read More

By: Judy Mathias
October 4, 2018
Share

FDA announces framework for strengthening medical device cybersecurity

Editor's Note The Food & Drug Administration (FDA) on October 1 released a “Playbook,” developed by the Medical Device Cybersecurity Regional Incident Preparedness and Response (MITRE) Corp, to assist hospitals and other healthcare providers respond to cybersecurity incidents involving medical devices, the American Hospital Association reports.  The MITRE Playbook outlines…

Read More

By: Judy Mathias
October 2, 2018
Share

FDA: Oscor Inc recalls TB-Temporary Bipolar Pacing Leads

Editor's Note The Food and Drug Administration (FDA) on September 27 announced the recall by Oscor Inc (Palm Harbor, Florida) of its TB-Temporary Bipolar Pacing Leads, with 2 mm unshrouded connectors. The recall was initiated because the connector cap housing may slide and expose the connection wire. This may cause…

Read More

By: Judy Mathias
September 28, 2018
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat